Research

Cellular

GLP-1 receptor agonists (GLP-1RAs) may help manage psoriasis (PsO) and psoriatic arthritis (PsA) in patients with obesity.

Clinicians may consider GLP-1RAs as a treatment option for obese patients with PsO and PsA.

StrongSupportsmedium confidence
Recent studies also suggest that GLP-1RAs may help manage PsO and PsA in patients with obesity.
Dimitri Luz Felipe da Silva et al. · The Journal of Rheumatology · 2025

Why this rating

The claim is based on recent studies, indicating a strong level of evidence.

Source

What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists

Dimitri Luz Felipe da Silva et al. · The Journal of Rheumatology · 2025

DOI 10.3899/jrheum.2025-0531

reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →